Wednesday , December 13 2017
Home / KEEP BUT DO NOT DISPLAY / Alerts / GLP-1 Albiglutide Review Time Extended

GLP-1 Albiglutide Review Time Extended

GLP-1 Albiglutide Review Time Extended

The FDA has extended the review time for GlaxoSmithKline’s (GSK) incretin mimetic once-weekly GLP-1 diabetes treatment albiglutide, delaying the deadline for delivering a verdict on the drug until April 15 next year.